Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800423 | 0.84 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2POLBMGLL | |
| SCHEMBL21964564 | 0.79 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2POLBMGLL | |
| SCHEMBL5578229 | 0.77 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2POLBMGLL | |
| SCHEMBL10874779 | 0.76 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2POLBKMT2A | |
| SCHEMBL27415197 | 0.74 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2POLBMGLL | |
| SCHEMBL22005630 | 0.74 | MAPT (0.51) | NPC1RAB9ASMN1; SMN2KMT2AMAOB | |
| SCHEMBL22857997 | 0.74 | CNR2 (0.53) | CNR2KMT2APTGDR2 | |
| SCHEMBL1490611 | 0.73 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2POLBMGLL | |
| SCHEMBL4493393 | 0.73 | MAPK8 (0.68) | NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL1267682 | 0.73 | SMN1; SMN2 (0.57) | NPC1RAB9ASMN1; SMN2POLBMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | US | disclosed |
| EP-3077394-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082411-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082411-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362408-A1 | ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | AADAC, PAH, CYP2C8 | NPC1 740/4885RAB9A 3625/4885SMN1; SMN2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.